CJC openJun 22, 2026

Glucagon-Like Peptide-1 Receptor Agonists Improve Heart Health in Heart Failure with Normal Pumping, Regardless of Diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 23, 2026

Abstract

Incretin-based therapies significantly reduced heart failure hospitalization and events, with a hazard ratio of 0.68.

No evidence was found that type 2 diabetes status modified the treatment effects of incretin-based therapies.
Pooled analyses indicated a significant reduction in cardiovascular death or heart failure hospitalization/events, with a hazard ratio of 0.76.
Observational data showed a notable reduction in heart failure hospitalization and events, with a hazard ratio of 0.60.
Exploratory network meta-analysis revealed no significant efficacy differences between individual incretin-based therapies.

Simplified

Heart failure (HF) with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF) is often associated with obesity and metabolic dysfunction. Recent data suggest that incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide improve cardiovascular outcomes in patients with HFpEF or HFmrEF both with and without diabetes. However, whether the effects differ by diabetes status across the broader literature remains unclear.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Featured in

GLP-1 Therapies

GLP-1 TherapiesIssue #43

Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

what lands in your inbox each week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients

2 days ago7 studies

Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group

1 week ago8 studies

New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients

2 weeks ago7 studies

GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery

3 weeks ago7 studies

Semaglutide linked to reduced cigarette craving in 24 smokers

4 weeks ago7 studies

Two-thirds of patients kept weight off after stopping GLP-1 drugs

5 weeks ago7 studies

Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months

7 weeks ago7 studies

Semaglutide linked to 2.5x higher risk of sudden vision loss

8 weeks ago7 studies

Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial

9 weeks ago7 studies

Semaglutide linked to 53% lower risk of death in dialysis patients with diabetes

10 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief